MannKind Corporation to Hold 2022 Second Quarter Financial Results Conference Call on August 9, 2022
MannKind Corporation (Nasdaq: MNKD) will announce its 2022 second-quarter financial results on August 9, 2022, at 5:00 PM Eastern Time. CEO Michael Castagna and CFO Steven Binder will lead a conference call to discuss these results and the company's updates. MannKind focuses on developing innovative therapies, particularly for conditions like diabetes and pulmonary arterial hypertension, leveraging its specialized dry-powder delivery technology. Investors can access the live call through the company’s website for detailed insights on performance and strategy.
- Focus on innovative therapeutic products targeting significant medical needs.
- Strong leadership with experienced CEO and CFO presenting financial results.
- None.
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Aug. 02, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) will release its 2022 second quarter and year to date financial results and its management will host a conference call to discuss these results and corporate updates at 5:00 PM (Eastern Time) on Tuesday, August 9, 2022.
Presenting from the Company will be its Chief Executive Officer, Michael Castagna and Chief Financial Officer, Steven Binder.
Those interested in listening to the conference call live via the Internet may do so by visiting the Company's website at https://mannkindcorp.com/news-events/ under Events.
About MannKind Corporation
MannKind Corporation (Nasdaq: MNKD) focuses on the development and commercialization of innovative therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases. We are committed to helping people manage serious health conditions – such as diabetes, pulmonary arterial hypertension (PAH) and idiopathic pulmonary fibrosis (IPF) – and experience life without limits.
Our approach begins with MannKind’s signature technology comprised of dry-powder formulation capabilities and inhalation device engineering that offers rapid and convenient delivery of medicines to the deep lung where they can exert an effect locally or enter the systemic circulation.
With a diverse pipeline, and a passionate team of Mannitarians collaborating nationwide, we are on a mission to give people control of their health and the freedom to live life.
Please visit mannkindcorp.com to learn more, and follow us on LinkedIn, Facebook, Twitter or Instagram.
For MannKind:
Rose Alinaya, Investor Relations
(818) 661-5000
Email: ir@mannkindcorp.com
FAQ
When will MannKind Corporation release its Q2 2022 financial results?
Who will present the financial results for MannKind Corporation?
How can I listen to MannKind Corporation's conference call?
What is the focus of MannKind Corporation's business?
